UroGen Pharma price target raised to $16 from $3 at Goldman Sachs
Goldman Sachs analyst Paul Choi raised the firm's price target on UroGen Pharma (URGN) to $16 from $3 and keeps a Neutral rating on the shares following yesterday's approval of Zusduri. The firm cites the stock being bid up (+22% following FDA approval of Zusduri in patients with low-grade intermediate-risk non muscle-invasive bladder cancer, which was surprising to most investor expectations given the negative ODAC advisory committee briefing document and vote that the drug's overall benefit-risk profile was not favorable, the analyst tells investors in a research note. Although the FDA is not obligated to follow the ODAC's recommendation, approvals following negative advisory committee meeting votes, particularly in oncology, are exceedingly rare, the firm adds.
Confident Investing Starts Here:
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Fitch Reaffirms The Bank of Nova Scotia (BNS)'s Credit Ratings; Outlook Steady
The Bank of Nova Scotia (NYSE:BNS) is one of the best Goldman Sachs bank stocks. On June 9, Fitch Ratings maintained the Bank of Nova Scotia's long-term and short-term issuer default ratings at 'AA-' and 'F1+', respectively, maintaining a stable outlook. These ratings indicate the constraints in Scotiabank's operating environment, reflected by its average operating environment score of 'aa-'. This score factors in the risks and revenue from primary end markets, such as Canada, the United States, Chile, Mexico, Peru, and Colombia. BNS maintains a leading retail banking position in Canada. Scotiabank is working on a five-year plan launched in December 2023 to grow its core businesses, strengthen relationships with clients, and improve how the bank operates. As part of this plan, BNS bought a 14.9% stake in KeyCorp (NYSE:KEY) and simplified its operations in Latin America by exiting Colombia, Costa Rica, and Panama. Fitch observed that, given its significant presence in Mexico, BNS could feel more of an impact from new US tariffs than other Canadian banks. Broader economic challenges in Mexico and Canada could also put pressure on the quality of its loan book. In Q2 2025, the percentage of impaired loans rose to 90bps, up from 83bps the year before, mostly due to weaker performance in Canadian retail and commercial lending. Credit quality has been a consistent challenge for BNS compared to other domestic banks, again tied to its international exposure. A businessman's hand pointing to a graph on a projector screen illustrating economic trends. Revenue at BNS has improved due to better loan management and stronger margins, but near-term profit pressure remains as the bank continues to realign its operations. To guard against tariff-related risks, it has increased loan-loss provisions. Capital levels are solid, with a CET1 ratio of 13.2%, providing a strong buffer in uncertain conditions. Fitch does not expect a ratings upgrade soon. A more optimistic outlook would require lower exposure to emerging markets and reduced risk from Canadian household debt and housing. While we acknowledge the potential of BNS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and , Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Fitch Reaffirms The Bank of Nova Scotia (BNS)'s Credit Ratings; Outlook Steady
The Bank of Nova Scotia (NYSE:BNS) is one of the best Goldman Sachs bank stocks. On June 9, Fitch Ratings maintained the Bank of Nova Scotia's long-term and short-term issuer default ratings at 'AA-' and 'F1+', respectively, maintaining a stable outlook. These ratings indicate the constraints in Scotiabank's operating environment, reflected by its average operating environment score of 'aa-'. This score factors in the risks and revenue from primary end markets, such as Canada, the United States, Chile, Mexico, Peru, and Colombia. BNS maintains a leading retail banking position in Canada. Scotiabank is working on a five-year plan launched in December 2023 to grow its core businesses, strengthen relationships with clients, and improve how the bank operates. As part of this plan, BNS bought a 14.9% stake in KeyCorp (NYSE:KEY) and simplified its operations in Latin America by exiting Colombia, Costa Rica, and Panama. Fitch observed that, given its significant presence in Mexico, BNS could feel more of an impact from new US tariffs than other Canadian banks. Broader economic challenges in Mexico and Canada could also put pressure on the quality of its loan book. In Q2 2025, the percentage of impaired loans rose to 90bps, up from 83bps the year before, mostly due to weaker performance in Canadian retail and commercial lending. Credit quality has been a consistent challenge for BNS compared to other domestic banks, again tied to its international exposure. A businessman's hand pointing to a graph on a projector screen illustrating economic trends. Revenue at BNS has improved due to better loan management and stronger margins, but near-term profit pressure remains as the bank continues to realign its operations. To guard against tariff-related risks, it has increased loan-loss provisions. Capital levels are solid, with a CET1 ratio of 13.2%, providing a strong buffer in uncertain conditions. Fitch does not expect a ratings upgrade soon. A more optimistic outlook would require lower exposure to emerging markets and reduced risk from Canadian household debt and housing. While we acknowledge the potential of BNS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and , Disclosure. None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
TD Cowen Confirms Buy Rating on JPMorgan Chase (JPM) on Continued Growth Trajectory
JPMorgan Chase & Co. (NYSE:JPM) is one of the best Goldman Sachs bank stocks. On June 11, TD Cowen reiterated a Buy rating on JPM with a $315 price target. The firm observed that JPMorgan maintains a record of "impressive organic growth momentum across its dominant businesses," indicated by its solid 41.4% return over last year and 13.32% YTD performance. TD Cowen identified JPMorgan's investments in artificial intelligence as a significant catalyst for long-term, exponential profitability. The firm also pointed to the bank's growing presence in private credit as a promising avenue for expansion, noting JPMorgan's financial resilience demonstrated by 55 consecutive years of maintaining its dividend. Supannee Hickman / The firm highlighted Jamie Dimon's leadership, emphasizing that his presentation at the investor conference reinforced their view of him as one of the most distinguished bankers of his generation, which led to its bullish outlook on JPMorgan. JPMorgan Chase & Co. (NYSE:JPM) is a global financial institution that specializes in offering banking, investment, and wealth management services to individuals, businesses, and governments worldwide. While we acknowledge the potential of JPM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
